| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardium | 29 | 2022 | 1204 | 2.670 |
Why?
|
| Heart Failure | 19 | 2023 | 1180 | 1.550 |
Why?
|
| Collagen | 13 | 2023 | 636 | 1.370 |
Why?
|
| Cardiomegaly | 13 | 2020 | 213 | 1.220 |
Why?
|
| Osteonectin | 10 | 2020 | 69 | 1.140 |
Why?
|
| Ventricular Function, Left | 10 | 2022 | 481 | 0.990 |
Why?
|
| Diastole | 10 | 2020 | 161 | 0.870 |
Why?
|
| Stroke Volume | 10 | 2022 | 586 | 0.770 |
Why?
|
| Systole | 7 | 2015 | 149 | 0.730 |
Why?
|
| Fibrillar Collagens | 5 | 2020 | 49 | 0.730 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2020 | 277 | 0.720 |
Why?
|
| Fibroblasts | 7 | 2023 | 902 | 0.710 |
Why?
|
| Myocytes, Cardiac | 14 | 2021 | 442 | 0.690 |
Why?
|
| Hypertrophy, Left Ventricular | 8 | 2022 | 140 | 0.660 |
Why?
|
| Fibrosis | 11 | 2022 | 371 | 0.650 |
Why?
|
| Procollagen | 5 | 2016 | 31 | 0.640 |
Why?
|
| Heart Ventricles | 9 | 2022 | 738 | 0.630 |
Why?
|
| Ventricular Remodeling | 9 | 2022 | 318 | 0.630 |
Why?
|
| Extracellular Matrix | 8 | 2023 | 493 | 0.620 |
Why?
|
| Ventricular Pressure | 7 | 2022 | 82 | 0.490 |
Why?
|
| Animals | 46 | 2023 | 20881 | 0.460 |
Why?
|
| Natriuretic Peptides | 1 | 2013 | 12 | 0.440 |
Why?
|
| Heart | 7 | 2018 | 850 | 0.430 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2012 | 21 | 0.420 |
Why?
|
| Mice | 28 | 2023 | 8474 | 0.400 |
Why?
|
| Microtubules | 6 | 2011 | 104 | 0.400 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2012 | 117 | 0.390 |
Why?
|
| Hemodynamics | 8 | 2021 | 705 | 0.370 |
Why?
|
| Biomarkers | 6 | 2022 | 1593 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 15 | 2022 | 2791 | 0.370 |
Why?
|
| Glycoproteins | 1 | 2012 | 238 | 0.370 |
Why?
|
| Aging | 5 | 2016 | 911 | 0.360 |
Why?
|
| Cats | 13 | 2015 | 292 | 0.350 |
Why?
|
| Kidney | 4 | 2018 | 945 | 0.330 |
Why?
|
| Tissue Engineering | 3 | 2023 | 212 | 0.310 |
Why?
|
| Angiotensinogen | 2 | 2017 | 18 | 0.280 |
Why?
|
| TRPP Cation Channels | 2 | 2017 | 20 | 0.280 |
Why?
|
| Disease Models, Animal | 12 | 2022 | 2550 | 0.260 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2015 | 39 | 0.250 |
Why?
|
| Myocardial Contraction | 5 | 2015 | 383 | 0.250 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2015 | 14 | 0.240 |
Why?
|
| Male | 31 | 2022 | 37321 | 0.240 |
Why?
|
| Cells, Cultured | 8 | 2023 | 2673 | 0.220 |
Why?
|
| Blood Pressure | 4 | 2020 | 1451 | 0.220 |
Why?
|
| Tetrazoles | 2 | 2016 | 160 | 0.220 |
Why?
|
| Female | 27 | 2022 | 38074 | 0.190 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2021 | 119 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 244 | 0.190 |
Why?
|
| Renin-Angiotensin System | 2 | 2018 | 79 | 0.180 |
Why?
|
| Vascular Remodeling | 1 | 2021 | 34 | 0.180 |
Why?
|
| Collagen Type I | 2 | 2015 | 175 | 0.180 |
Why?
|
| Heart Failure, Diastolic | 2 | 2011 | 14 | 0.180 |
Why?
|
| Muscle Contraction | 1 | 2021 | 210 | 0.180 |
Why?
|
| Ubiquitination | 2 | 2011 | 85 | 0.170 |
Why?
|
| Mutation | 4 | 2021 | 1213 | 0.170 |
Why?
|
| Protein Biosynthesis | 2 | 2012 | 181 | 0.170 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 329 | 0.170 |
Why?
|
| Formoterol Fumarate | 1 | 2019 | 25 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2018 | 483 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 27 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 77 | 0.160 |
Why?
|
| Humans | 28 | 2022 | 68618 | 0.160 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 157 | 0.160 |
Why?
|
| Caveolin 1 | 1 | 2018 | 59 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2021 | 276 | 0.160 |
Why?
|
| Macrophages | 2 | 2020 | 647 | 0.150 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 221 | 0.150 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2016 | 95 | 0.150 |
Why?
|
| Podocytes | 1 | 2019 | 113 | 0.150 |
Why?
|
| Angiotensin II | 1 | 2018 | 220 | 0.150 |
Why?
|
| Fumarates | 1 | 2017 | 28 | 0.150 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2017 | 25 | 0.150 |
Why?
|
| Hypertension | 3 | 2022 | 1535 | 0.150 |
Why?
|
| Renin | 1 | 2017 | 96 | 0.150 |
Why?
|
| Muscle Proteins | 3 | 2012 | 94 | 0.150 |
Why?
|
| Mice, Knockout | 7 | 2017 | 1692 | 0.140 |
Why?
|
| Hospice Care | 1 | 2017 | 29 | 0.140 |
Why?
|
| Amides | 1 | 2017 | 86 | 0.140 |
Why?
|
| Aged | 13 | 2022 | 14862 | 0.140 |
Why?
|
| ADAMTS1 Protein | 1 | 2016 | 9 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2018 | 1664 | 0.130 |
Why?
|
| Cardiography, Impedance | 1 | 2015 | 14 | 0.130 |
Why?
|
| Lactosylceramides | 1 | 2016 | 27 | 0.130 |
Why?
|
| Telemetry | 1 | 2015 | 23 | 0.130 |
Why?
|
| Cytokines | 1 | 2020 | 866 | 0.130 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 53 | 0.130 |
Why?
|
| RNA | 2 | 2014 | 171 | 0.130 |
Why?
|
| Valsartan | 1 | 2016 | 99 | 0.130 |
Why?
|
| Pressure | 3 | 2012 | 252 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 219 | 0.130 |
Why?
|
| Mice, Transgenic | 7 | 2014 | 1033 | 0.130 |
Why?
|
| Prognosis | 3 | 2022 | 2093 | 0.130 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 307 | 0.130 |
Why?
|
| Lung | 1 | 2020 | 849 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2011 | 114 | 0.130 |
Why?
|
| Aminobutyrates | 1 | 2016 | 94 | 0.130 |
Why?
|
| Periodontal Ligament | 1 | 2015 | 16 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.130 |
Why?
|
| Middle Aged | 13 | 2022 | 21147 | 0.120 |
Why?
|
| Macrophages, Peritoneal | 1 | 2015 | 67 | 0.120 |
Why?
|
| Connectin | 1 | 2015 | 14 | 0.120 |
Why?
|
| Biphenyl Compounds | 2 | 2016 | 184 | 0.120 |
Why?
|
| Transglutaminases | 1 | 2015 | 67 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 155 | 0.120 |
Why?
|
| Myocarditis | 1 | 2015 | 49 | 0.120 |
Why?
|
| Palliative Care | 1 | 2017 | 271 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2009 | 247 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 142 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 116 | 0.120 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.120 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2014 | 17 | 0.120 |
Why?
|
| Isoxazoles | 1 | 2014 | 22 | 0.120 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 85 | 0.110 |
Why?
|
| Tubulin | 3 | 2011 | 60 | 0.110 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2014 | 44 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 76 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 158 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 592 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 1293 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1465 | 0.110 |
Why?
|
| Time Factors | 4 | 2017 | 4655 | 0.110 |
Why?
|
| Echocardiography | 5 | 2014 | 515 | 0.110 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2012 | 17 | 0.110 |
Why?
|
| Fibrinolysin | 2 | 2003 | 33 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2012 | 103 | 0.100 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2012 | 62 | 0.100 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2011 | 4 | 0.100 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2011 | 7 | 0.100 |
Why?
|
| Enzyme Induction | 1 | 2012 | 119 | 0.100 |
Why?
|
| Signal Transduction | 7 | 2019 | 2689 | 0.100 |
Why?
|
| Proteolysis | 1 | 2012 | 97 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2022 | 1174 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 74 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2017 | 1330 | 0.100 |
Why?
|
| Propranolol | 1 | 2011 | 103 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 529 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2015 | 284 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2022 | 1553 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 2012 | 119 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 216 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2015 | 753 | 0.090 |
Why?
|
| Integrin beta3 | 2 | 2009 | 35 | 0.090 |
Why?
|
| Autophagy | 1 | 2012 | 208 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 447 | 0.090 |
Why?
|
| Sirolimus | 1 | 2011 | 118 | 0.090 |
Why?
|
| Elasticity | 5 | 2015 | 103 | 0.090 |
Why?
|
| Veterans | 1 | 2017 | 904 | 0.090 |
Why?
|
| Phenotype | 4 | 2017 | 947 | 0.080 |
Why?
|
| Bone Marrow Cells | 2 | 2020 | 217 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 331 | 0.080 |
Why?
|
| Proteome | 1 | 2009 | 87 | 0.080 |
Why?
|
| Myosin Heavy Chains | 2 | 2012 | 49 | 0.080 |
Why?
|
| Heart Function Tests | 2 | 2005 | 33 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2009 | 111 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 209 | 0.080 |
Why?
|
| Proteomics | 1 | 2009 | 246 | 0.070 |
Why?
|
| Proteins | 1 | 2011 | 474 | 0.070 |
Why?
|
| Rats | 5 | 2011 | 5300 | 0.070 |
Why?
|
| Exercise | 1 | 2013 | 658 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 196 | 0.070 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2006 | 43 | 0.070 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2006 | 69 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2016 | 682 | 0.070 |
Why?
|
| Cardiac Catheterization | 2 | 2021 | 419 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7029 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2012 | 954 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 328 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2021 | 601 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2020 | 7277 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 2 | 2003 | 223 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2015 | 246 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2003 | 791 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2005 | 141 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2017 | 118 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2017 | 239 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 3705 | 0.060 |
Why?
|
| Microscopy, Confocal | 3 | 2012 | 337 | 0.050 |
Why?
|
| Muscle Cells | 1 | 2003 | 30 | 0.050 |
Why?
|
| Exercise Tolerance | 2 | 2014 | 75 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2012 | 282 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 4848 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2016 | 282 | 0.050 |
Why?
|
| Bioreactors | 1 | 2023 | 65 | 0.050 |
Why?
|
| Stress, Mechanical | 1 | 2023 | 208 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1034 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 579 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 765 | 0.050 |
Why?
|
| Apoptosis | 2 | 2019 | 1641 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3259 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 1999 | 324 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2016 | 1738 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 45 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2015 | 189 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 170 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2011 | 40 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 149 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1864 | 0.040 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2021 | 174 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2020 | 131 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2015 | 1200 | 0.040 |
Why?
|
| Organ Size | 2 | 2012 | 242 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 377 | 0.040 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1999 | 19 | 0.040 |
Why?
|
| Hypertrophy | 2 | 2011 | 89 | 0.040 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 51 | 0.040 |
Why?
|
| Organelle Biogenesis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 34 | 0.040 |
Why?
|
| Angiotensins | 1 | 2018 | 16 | 0.040 |
Why?
|
| Integrins | 1 | 1999 | 115 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 21403 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2018 | 69 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 100 | 0.040 |
Why?
|
| Antigens, CD | 1 | 1999 | 230 | 0.040 |
Why?
|
| Sarcomeres | 2 | 2011 | 32 | 0.040 |
Why?
|
| Constriction | 2 | 2012 | 37 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 231 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2017 | 48 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 615 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2017 | 103 | 0.040 |
Why?
|
| Cell Size | 2 | 2012 | 76 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2012 | 453 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 98 | 0.030 |
Why?
|
| Galectins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2016 | 7 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2016 | 47 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2016 | 144 | 0.030 |
Why?
|
| Cell Movement | 1 | 2018 | 630 | 0.030 |
Why?
|
| Neutral Ceramidase | 1 | 2016 | 27 | 0.030 |
Why?
|
| Lisinopril | 1 | 2015 | 16 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1851 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2015 | 22 | 0.030 |
Why?
|
| Actins | 2 | 2008 | 249 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 94 | 0.030 |
Why?
|
| Manometry | 1 | 2017 | 276 | 0.030 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2015 | 38 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 144 | 0.030 |
Why?
|
| Compliance | 1 | 2015 | 26 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 145 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1752 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 166 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 304 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 2007 | 0.030 |
Why?
|
| Tensile Strength | 2 | 2009 | 90 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 241 | 0.030 |
Why?
|
| Electric Countershock | 1 | 2015 | 130 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 248 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 978 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 99 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 202 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 536 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2014 | 21 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 218 | 0.030 |
Why?
|
| Collagen Type IV | 1 | 2014 | 28 | 0.030 |
Why?
|
| Hypoxia | 1 | 2015 | 169 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 786 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 135 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 442 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5731 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 792 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 254 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2014 | 235 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 249 | 0.030 |
Why?
|
| Myristic Acid | 1 | 2012 | 6 | 0.030 |
Why?
|
| Fibronectins | 2 | 2006 | 130 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2013 | 133 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 540 | 0.030 |
Why?
|
| Pulmonary Artery | 2 | 2008 | 323 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 622 | 0.030 |
Why?
|
| Viscosity | 2 | 2002 | 72 | 0.030 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2012 | 7 | 0.030 |
Why?
|
| Purkinje Fibers | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2012 | 11 | 0.030 |
Why?
|
| Connexins | 1 | 2012 | 35 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2011 | 14 | 0.030 |
Why?
|
| Protein Phosphatase 1 | 1 | 2011 | 36 | 0.020 |
Why?
|
| Cell Survival | 2 | 2009 | 901 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2011 | 163 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 87 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2011 | 92 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 102 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 67 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1040 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 130 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 319 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2011 | 104 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 2012 | 113 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2012 | 215 | 0.020 |
Why?
|
| Action Potentials | 1 | 2012 | 223 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 233 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 99 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 252 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2010 | 251 | 0.020 |
Why?
|
| Calpain | 1 | 2011 | 205 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2009 | 24 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2009 | 25 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2009 | 30 | 0.020 |
Why?
|
| Alginates | 1 | 2009 | 35 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2012 | 337 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 49 | 0.020 |
Why?
|
| Homeostasis | 1 | 2011 | 291 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 47 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 65 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 284 | 0.020 |
Why?
|
| Hydrogels | 1 | 2009 | 54 | 0.020 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 101 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1030 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 152 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2009 | 133 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 689 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 226 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2009 | 301 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 94 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 262 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 351 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2007 | 81 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 155 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 1619 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 514 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 306 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 432 | 0.020 |
Why?
|
| Calcium | 2 | 2003 | 929 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2006 | 95 | 0.020 |
Why?
|
| Transgenes | 1 | 2006 | 92 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 52 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 191 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1047 | 0.020 |
Why?
|
| Aorta | 1 | 2007 | 316 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 176 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 215 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 295 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 786 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 2358 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 981 | 0.020 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.020 |
Why?
|
| Base Sequence | 1 | 2006 | 1015 | 0.020 |
Why?
|
| Culture Techniques | 1 | 2004 | 65 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 1447 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 384 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 700 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1085 | 0.010 |
Why?
|
| Isomerism | 1 | 2003 | 63 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 2003 | 53 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 2002 | 30 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 2002 | 33 | 0.010 |
Why?
|
| Colchicine | 1 | 2002 | 48 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2002 | 236 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 368 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1753 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 770 | 0.010 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 1999 | 2 | 0.010 |
Why?
|
| Vitronectin | 1 | 1999 | 12 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1999 | 48 | 0.010 |
Why?
|
| Culture Media | 1 | 1999 | 155 | 0.010 |
Why?
|
| Diacetyl | 1 | 1998 | 6 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1998 | 29 | 0.010 |
Why?
|
| Sepharose | 1 | 1998 | 18 | 0.010 |
Why?
|
| Gels | 1 | 1998 | 55 | 0.010 |
Why?
|
| Cell Physiological Phenomena | 1 | 1998 | 19 | 0.010 |
Why?
|